Treatment of men with rising prostate-specific antigen levels following radical prostatectomy

References

• Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J. Clin.60(5), 277–300 (2010).
   PubMed Web of Science ®Google Scholar
• Choo R. Salvage radiotherapy for patients with PSA relapse following radical prostatectomy: issues and challenges. Cancer Res. Treat.42(1), 1–11 (2010).
   PubMed Web of Science ®Google Scholar
• Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA281(17), 1591–1597 (1999).
   PubMed Web of Science ®Google Scholar
• Ward JF, Blute ML, Slezak J, Bergstralh EJ, Zincke H. The long-term clinical impact of biochemical recurrence of prostate cancer 5 or more years after radical prostatectomy. J. Urol.170(5), 1872–1876 (2003).
   PubMed Web of Science ®Google Scholar
• Dreicer R. Controversies in the systemic management of patients with evidence of biochemical failure following radical prostatectomy. Cancer Treat. Rev.28(4), 189–194 (2002).
   PubMed Web of Science ®Google Scholar
• Partin AW, Oesterling JE. The clinical usefulness of prostate specific antigen: update 1994. J. Urol.152(5 Pt 1), 1358–1368 (1994).
   PubMed Web of Science ®Google Scholar
• Freedland SJ, Sutter ME, Dorey F, Aronson WJ. Defining the ideal cutpoint for determining PSA recurrence after radical prostatectomy. Prostate-specific antigen. Urology61(2), 365–369 (2003).
   PubMed Web of Science ®Google Scholar
• Boccon-Gibod L, Djavan WB, Hammerer P et al. Management of prostate-specific antigen relapse in prostate cancer: a European Consensus. Int. J. Clin. Pract.58(4), 382–390 (2004).
   PubMed Web of Science ®Google Scholar
• Heidenreich A, Aus G, Bolla M et al. EAU guidelines on prostate cancer. Eur. Urol.53(1), 68–80 (2008).
   PubMed Web of Science ®Google Scholar
• Cookson MS, Aus G, Burnett AL et al. Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the reporting of surgical outcomes. J. Urol.177(2), 540–545 (2007).
   PubMed Web of Science ®Google Scholar
• Amling CL, Bergstralh EJ, Blute ML, Slezak JM, Zincke H. Defining prostate specific antigen progression after radical prostatectomy: what is the most appropriate cut point? J. Urol.165(4), 1146–1151 (2001).
   PubMed Web of Science ®Google Scholar
• Stephenson AJ, Kattan MW, Eastham JA et al. Defining biochemical recurrence of prostate cancer after radical prostatectomy: a proposal for a standardized definition. J. Clin. Oncol.24(24), 3973–3978 (2006).
   PubMed Web of Science ®Google Scholar
• Cox JD, Gallagher MJ, Hammond EH, Kaplan RS, Schellhammer PF. Consensus statements on radiation therapy of prostate cancer: guidelines for prostate re-biopsy after radiation and for radiation therapy with rising prostate-specific antigen levels after radical prostatectomy. American Society for Therapeutic Radiology and Oncology Consensus Panel. J. Clin. Oncol.17(4), 1155 (1999).
   PubMed Web of Science ®Google Scholar
• Freedland SJ, Humphreys EB, Mangold LA et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA294(4), 433–439 (2005).
   PubMed Web of Science ®Google Scholar
• Beresford MJ, Gillatt D, Benson RJ, Ajithkumar T. A systematic review of the role of imaging before salvage radiotherapy for post-prostatectomy biochemical recurrence. Clin. Oncol. (R. Coll. Radiol.)22(1), 46–55 (2010).
   PubMed Web of Science ®Google Scholar
• Kane CJ, Amling CL, Johnstone PA et al. Limited value of bone scintigraphy and computed tomography in assessing biochemical failure after radical prostatectomy. Urology61(3), 607–611 (2003).
   PubMed Web of Science ®Google Scholar
• Johnstone PA, Tarman GJ, Riffenburgh RH, Rohde DC, Puckett ML, Kane CJ. Yield of imaging and scintigraphy assessing biochemical failure in prostate cancer patients. Urol. Oncol.3(4), 108–1112 (1997).
   PubMedGoogle Scholar
• Cher ML, Bianco FJ Jr, Lam JS et al. Limited role of radionuclide bone scintigraphy in patients with prostate specific antigen elevations after radical prostatectomy. J. Urol.160(4), 1387–1391 (1998).
   PubMed Web of Science ®Google Scholar
• Gomez P, Manoharan M, Kim SS, Soloway MS. Radionuclide bone scintigraphy in patients with biochemical recurrence after radical prostatectomy: when is it indicated? BJU Int.94(3), 299–302 (2004).
   PubMed Web of Science ®Google Scholar
• Okotie OT, Aronson WJ, Wieder JA et al. Predictors of metastatic disease in men with biochemical failure following radical prostatectomy. J. Urol.171(6 Pt 1), 2260–2264 (2004).
   PubMed Web of Science ®Google Scholar
• Sella T, Schwartz LH, Swindle PW et al. Suspected local recurrence after radical prostatectomy: endorectal coil MR imaging. Radiology231(2), 379–385 (2004).
   PubMed Web of Science ®Google Scholar
• Casciani E, Polettini E, Carmenini E et al. Endorectal and dynamic contrast-enhanced MRI for detection of local recurrence after radical prostatectomy. AJR Am. J. Roentgenol.190(5), 1187–1192 (2008).
   PubMed Web of Science ®Google Scholar
• Cirillo S, Petracchini M, Scotti L et al. Endorectal magnetic resonance imaging at 1.5 Tesla to assess local recurrence following radical prostatectomy using T2-weighted and contrast-enhanced imaging. Eur. Radiol.19(3), 761–769 (2009).
   PubMed Web of Science ®Google Scholar
• Parker AS, Heckman MG, Wu KJ et al. Evaluation of Ki-67 staining levels as an independent biomarker of biochemical recurrence after salvage radiation therapy for prostate cancer. Int. J. Radiat. Oncol. Biol. Phys.75(5), 1364–1370 (2009).
   PubMed Web of Science ®Google Scholar
• Buskirk SJ, Pisansky TM, Schild SE et al. Salvage radiotherapy for isolated prostate specific antigen increase after radical prostatectomy: evaluation of prognostic factors and creation of a prognostic scoring system. J. Urol.176(3), 985–990 (2006).
   PubMed Web of Science ®Google Scholar
• Stephenson AJ, Scardino PT, Kattan MW et al. Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J. Clin. Oncol.25(15), 2035–2041 (2007).
   PubMed Web of Science ®Google Scholar
• Zang X, Thompson RH, Al-Ahmadie HA et al. B7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome. Proc. Natl Acad. Sci. USA104(49), 19458–19463 (2007).
   PubMed Web of Science ®Google Scholar
• Roth TJ, Sheinin Y, Lohse CM et al. B7-H3 ligand expression by prostate cancer: a novel marker of prognosis and potential target for therapy. Cancer Res.67(16), 7893–7900 (2007).
   PubMed Web of Science ®Google Scholar
• Parker AS, Heckman MG, Sheinin Y et al. Evaluation of B7-H3 expression as a biomarker of biochemical recurrence after salvage radiation therapy for recurrent prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. DOI: 10.1016/j.ijrobp.2010.01.061 (2010) (Epub ahead of print).
   Google Scholar
• Khor LY, Bae K, Pollack A et al. COX-2 expression predicts prostate-cancer outcome: analysis of data from the RTOG 92–02 trial. Lancet Oncol.8(10), 912–920 (2007).
   PubMed Web of Science ®Google Scholar
• Pruthi RS, Derksen JE, Moore D et al. Phase II trial of celecoxib in prostate-specific antigen recurrent prostate cancer after definitive radiation therapy or radical prostatectomy. Clin. Cancer Res.12(7 Pt 1), 2172–2177 (2006).
   PubMed Web of Science ®Google Scholar
• Madaan S, Abel PD, Chaudhary KS et al. Cytoplasmic induction and over-expression of cyclooxygenase-2 in human prostate cancer: implications for prevention and treatment. BJU Int.86(6), 736–741 (2000).
   PubMed Web of Science ®Google Scholar
• Trock BJ, Han M, Freedland SJ et al. Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy. JAMA299(23), 2760–2769 (2008).
   PubMed Web of Science ®Google Scholar
• Anscher MS, Clough R, Dodge R. Radiotherapy for a rising prostate-specific antigen after radical prostatectomy: the first 10 years. Int. J. Radiat. Oncol. Biol. Phys.48(2), 369–375 (2000).
   PubMed Web of Science ®Google Scholar
• Chawla AK, Thakral HK, Zietman AL, Shipley WU. Salvage radiotherapy after radical prostatectomy for prostate adenocarcinoma: analysis of efficacy and prognostic factors. Urology59(5), 726–731 (2002).
   PubMed Web of Science ®Google Scholar
• Neuhof D, Hentschel T, Bischof M, Sroka-Perez G, Hohenfellner M, Debus J. Long-term results and predictive factors of three-dimensional conformal salvage radiotherapy for biochemical relapse after prostatectomy. Int. J. Radiat. Oncol. Biol. Phys.67(5), 1411–1417 (2007).
   PubMed Web of Science ®Google Scholar
• Ward JF, Zincke H, Bergstralh EJ, Slezak JM, Blute ML. Prostate specific antigen doubling time subsequent to radical prostatectomy as a prognosticator of outcome following salvage radiotherapy. J. Urol.172(6 Pt 1), 2244–2248 (2004).
   PubMed Web of Science ®Google Scholar
• Pisansky TM, Kozelsky TF, Myers RP et al. Radiotherapy for isolated serum prostate specific antigen elevation after prostatectomy for prostate cancer. J. Urol.163(3), 845–850 (2000).
   PubMed Web of Science ®Google Scholar
• De Meerleer G, Fonteyne V, Meersschout S et al. Salvage intensity-modulated radiotherapy for rising PSA after radical prostatectomy. Radiother. Oncol.89(2), 205–213 (2008).
   PubMed Web of Science ®Google Scholar
• Peyromaure M, Allouch M, Eschwege F, Verpillat P, Debre B, Zerbib M. Salvage radiotherapy for biochemical recurrence after radical prostatectomy: a study of 62 patients. Urology62(3), 503–507 (2003).
   PubMed Web of Science ®Google Scholar
• Brooks JP, Albert PS, Wilder RB, Gant DA, McLeod DG, Poggi MM. Long-term salvage radiotherapy outcome after radical prostatectomy and relapse predictors. J. Urol.174(6), 2204–2208; discussion 2208 (2005).
   PubMed Web of Science ®Google Scholar
• Tsien C, Griffith KA, Sandler HM et al. Long-term results of three-dimensional conformal adjuvant and salvage radiotherapy after radical prostatectomy. Urology62(1), 93–98 (2003).
   PubMed Web of Science ®Google Scholar
• Catton C, Gospodarowicz M, Warde P et al. Adjuvant and salvage radiation therapy after radical prostatectomy for adenocarcinoma of the prostate. Radiother. Oncol.59(1), 51–60 (2001).
   PubMed Web of Science ®Google Scholar
• Song DY, Thompson TL, Ramakrishnan V et al. Salvage radiotherapy for rising or persistent PSA after radical prostatectomy. Urology60(2), 281–287 (2002).
   PubMed Web of Science ®Google Scholar
• Do T, Parker RG, Do C, Tran L, Do L, Dolkar D. Salvage radiotherapy for biochemical and clinical failures following radical prostatectomy. Cancer J. Sci. Am.4(5), 324–330 (1998).
   PubMed Web of Science ®Google Scholar
• Leventis AK, Shariat SF, Kattan MW, Butler EB, Wheeler TM, Slawin KM. Prediction of response to salvage radiation therapy in patients with prostate cancer recurrence after radical prostatectomy. J. Clin. Oncol.19(4), 1030–1039 (2001).
   PubMed Web of Science ®Google Scholar
• Quero L, Mongiat-Artus P, Ravery V, Maylin C, Desgrandchamps F, Hennequin C. Salvage radiotherapy for patients with PSA relapse after radical prostatectomy: a single institution experience. BMC Cancer8, 26 (2008).
   PubMedGoogle Scholar
• Maier J, Forman J, Tekyi-Mensah S, Bolton S, Patel R, Pontes JE. Salvage radiation for a rising PSA following radical prostatectomy. Urol. Oncol.22(1), 50–56 (2004).
   PubMed Web of Science ®Google Scholar
• Pazona JF, Han M, Hawkins SA, Roehl KA, Catalona WJ. Salvage radiation therapy for prostate specific antigen progression following radical prostatectomy: 10-year outcome estimates. J. Urol.174(4 Pt 1), 1282–1286 (2005).
   PubMed Web of Science ®Google Scholar
• Katz MS, Zelefsky MJ, Venkatraman ES, Fuks Z, Hummer A, Leibel SA. Predictors of biochemical outcome with salvage conformal radiotherapy after radical prostatectomy for prostate cancer. J. Clin. Oncol.21(3), 483–489 (2003).
   PubMed Web of Science ®Google Scholar
• Bernard JR Jr, Buskirk SJ, Heckman MG et al. Salvage radiotherapy for rising prostate-specific antigen levels after radical prostatectomy for prostate cancer: dose-response analysis. Int. J. Radiat. Oncol. Biol. Phys.76(3), 735–740 (2010).
   PubMed Web of Science ®Google Scholar
• King CR, Spiotto MT. Improved outcomes with higher doses for salvage radiotherapy after prostatectomy. Int. J. Radiat. Oncol. Biol. Phys.71(1), 23–27 (2008).
   PubMed Web of Science ®Google Scholar
• Wong GW, Palazzi-Churas KL, Jarrard DF et al. Salvage hypofractionated radiotherapy for biochemically recurrent prostate cancer after radical prostatectomy. Int. J. Radiat. Oncol. Biol. Phys.70(2), 449–455 (2008).
   PubMed Web of Science ®Google Scholar
• Lee LW, McBain CA, Swindell R, Wylie JP, Cowan RA, Logue JP. Hypofractionated radiotherapy as salvage for rising prostate-specific antigen after radical prostatectomy. Clin. Oncol. (R. Coll. Radiol.)16(8), 517–522 (2004).
   PubMed Web of Science ®Google Scholar
• Syndikus I, Pickles T, Kostashuk E, Sullivan LD. Postoperative radiotherapy for stage pT3 carcinoma of the prostate: improved local control. J. Urol.155(6), 1983–1986 (1996).
   PubMed Web of Science ®Google Scholar
• Peterson JL, Buskirk SJ, Heckman MG et al. Late toxicity after postprostatectomy salvage radiation therapy. Radiother. Oncol.93(2), 203–206 (2009).
   PubMed Web of Science ®Google Scholar
• Choo R, Danjoux C, Gardner S et al. Efficacy of salvage radiotherapy plus 2-year androgen suppression for postradical prostatectomy patients with PSA relapse. Int. J. Radiat. Oncol. Biol. Phys.75(4), 983–989 (2009).
   PubMed Web of Science ®Google Scholar
• Yokomizo A, Kawamoto H, Nihei K et al. Randomized controlled trial to evaluate radiotherapy +/- endocrine therapy versus endocrine therapy alone for PSA failure after radical prostatectomy: Japan Clinical Oncology Group Study JCOG 0401. Jpn. J. Clin. Oncol.35(1), 34–36 (2005).
   PubMed Web of Science ®Google Scholar
• Parker C, Sydes MR, Catton C et al. Radiotherapy and androgen deprivation in combination after local surgery (RADICALS): a new Medical Research Council/National Cancer Institute of Canada Phase III trial of adjuvant treatment after radical prostatectomy. BJU Int.99(6), 1376–1379 (2007).
   PubMed Web of Science ®Google Scholar
• Van Poppel H, Joniau S, Van Cleynenbreugel B, Mottaghy FM, Oyen R. Diagnostic evaluation of PSA recurrence and review of hormonal management after radical prostatectomy. Prostate Cancer Prostatic Dis.12(2), 116–123 (2009).
   PubMed Web of Science ®Google Scholar
• Moul JW, Wu H, Sun L et al. Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy. J. Urol.171(3), 1141–1147 (2004).
   PubMed Web of Science ®Google Scholar
• Siddiqui SA, Boorjian SA, Inman B, Bagniewski S, Bergstralh EJ, Blute ML. Timing of androgen deprivation therapy and its impact on survival after radical prostatectomy: a matched cohort study. J. Urol.179(5), 1830–1837; discussion 1837 (2008).
   PubMed Web of Science ®Google Scholar
• Shepard DR, Raghavan D. Innovations in the systemic therapy of prostate cancer. Nat. Rev. Clin. Oncol.7(1), 13–21 (2010).
   PubMed Web of Science ®Google Scholar
• Scher HI, Beer TM, Higano CS et al. Antitumor activity of MDV3100 in a Phase I/II study of castration-resistant prostate cancer (CRPC). J. Clin. Oncol.27(15s), (2009) (Abstract 5011).
   Google Scholar
• Pendleton JM, Tan WW, Anai S et al. Phase II trial of isoflavone in prostate-specific antigen recurrent prostate cancer after previous local therapy. BMC Cancer8, 132 (2008).
   PubMed Web of Science ®Google Scholar
• Schroder FH, Roobol MJ, Boeve ER et al. Randomized, double-blind, placebo-controlled crossover study in men with prostate cancer and rising PSA: effectiveness of a dietary supplement. Eur. Urol.48(6), 922–930 (2005).
   PubMed Web of Science ®Google Scholar
• Vaishampayan U, Hussain M, Banerjee M et al. Lycopene and soy isoflavones in the treatment of prostate cancer. Nutr. Cancer59(1), 1–7 (2007).
   PubMed Web of Science ®Google Scholar
• Pantuck AJ, Leppert JT, Zomorodian N et al. Phase II study of pomegranate juice for men with rising prostate-specific antigen following surgery or radiation for prostate cancer. Clin. Cancer Res.12(13), 4018–4026 (2006).
   PubMed Web of Science ®Google Scholar
• Smith MR, Manola J, Kaufman DS, Oh WK, Bubley GJ, Kantoff PW. Celecoxib versus placebo for men with prostate cancer and a rising serum prostate-specific antigen after radical prostatectomy and/or radiation therapy. J. Clin. Oncol.24(18), 2723–2728 (2006).
   PubMed Web of Science ®Google Scholar
• Srinivas S, Feldman D. A Phase II trial of calcitriol and naproxen in recurrent prostate cancer. Anticancer Res.29(9), 3605–3610 (2009).
   PubMed Web of Science ®Google Scholar
• Banez LL, Blake GW, McLeod DG, Crawford ED, Moul JW. Combined low-dose flutamide plus finasteride vs low-dose flutamide monotherapy for recurrent prostate cancer: a comparative analysis of two Phase II trials with a long-term follow-up. BJU Int.104(3), 310–314 (2009).
   PubMed Web of Science ®Google Scholar
• Schroder FH, Bangma CH, Wolff JM et al. Can dutasteride delay or prevent the progression of prostate cancer in patients with biochemical failure after radical therapy? Rationale and design of the Avodart after Radical Therapy for Prostate Cancer Study. BJU Int.103(5), 590–596 (2009).
   PubMed Web of Science ®Google Scholar
• Siemens DR, Heaton JP, Adams MA, Kawakami J, Graham CH. Phase II study of nitric oxide donor for men with increasing prostate-specific antigen level after surgery or radiotherapy for prostate cancer. Urology74(4), 878–883 (2009).
   PubMed Web of Science ®Google Scholar
• Kantoff P, Higano C, Shore N et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med.363(5), 411–422 (2010).
   PubMed Web of Science ®Google Scholar
• North SA, Graham K, Bodnar D, Venner P. A pilot study of the liposomal MUC1 vaccine BLP25 in prostate specific antigen failures after radical prostatectomy. J. Urol.176(1), 91–95 (2006).
   PubMed Web of Science ®Google Scholar
• Kirschenbaum A, Itzkowitz SH, Wang JP, Yao S, Eliashvili M, Levine AC. MUC1 expression in prostate carcinoma: correlation with grade and stage. Mol. Urol.3(3), 163–168 (1999).
   PubMedGoogle Scholar
• Vishnu P, Tan WW. Update on options for treatment of metastatic castration-resistant prostate cancer. Onco Targets Ther.3, 39–51 (2010).
   PubMed Web of Science ®Google Scholar
• Taylor N, Kelly JF, Kuban DA, Babaian RJ, Pisters LL, Pollack A. Adjuvant and salvage radiotherapy after radical prostatectomy for prostate cancer. Int. J. Radiat. Oncol. Biol. Phys.56(3), 755–763 (2003).
   PubMed Web of Science ®Google Scholar
• Moreira DM, Jayachandran J, Presti JC Jr et al. Validation of a nomogram to predict disease progression following salvage radiotherapy after radical prostatectomy: results from the SEARCH database. BJU Int.104(10), 1452–1456 (2009).
   PubMed Web of Science ®Google Scholar